Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Doles Out $32M in New Sequencing Grants; Adds to Last Year s $38M Funding

NEW YORK, Aug. 8 (GenomeWeb News) - The National Human Genome Research Institute has awarded grants totaling more than $32 million to advance the development of new technologies designed to cut the cost of DNA sequencing and expand the use of genomics in biomedical research and healthcare.

 

According to the NHGRI, the cost of DNA sequencing has fallen more than 50-fold over the past 10 years. However, it still costs about $10 million to sequence 3 billion base pairs. These grants add to the $38 million the NGHRI issued last October to help pay for the development on newer sequencing technologies.

 

The NHGRI said it would like to see the cost of sequencing a mammalian-sized genome cut to $100,000 in the near-term. Among the researchers who received grants to achieve this goal are Agencourt Personal Genomics' Gina Costa, who received a commitment of $1.2 million over two years; the State University of New York's Vera Gorfinkle, who received a 2-year grant worth $1.5 million; and Network Biosystems' Greg Kellogg, who received a $4.5 million, 3-year grant.

 

The NHGRI also awarded numerous grants to researchers looking to cut the cost of sequencing a mammalian-sized genome to $1,000 or less. Among these grant recipients are Duke University's Richard Fair, who was awarded a $510,000, 2-year grant; Reza Ghadiri from the Scripps Research Institute and Oxford University's Hagan Bayley, who received a 5-year grant worth $4.2 million; and Stephen Turner of Nanofluidics, who received a 3-year grant worth $6.6 million.

 

Additional details about the grants and their recipients can be found here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more